

Dynamics of the nitroergic system in experimental hypercholesterolemia

Baykulov Azim Kenjayeich

Department of Pharmaceutical and Toxicological Chemistry, Samarkand State Medical University, Samarkand, Uzbekistan.

Accepted 29 August, 2023

ABSTRACT

Hypercholesterolemia and atherosclerosis remain the main cause of mortality in Central Asia. Our objective was to study the molecular mechanisms of endothelial dysfunction with changes in the nitroergic system in experimental hypercholesterolemia. The experiments were carried out on 28 Chinchilla rabbits with an average weight of 2.5-3.0kg. The action of drugs was studied in dynamics: the initial 3-month condition and after one month of drug administration. The results obtained were compared with those of the control and intact groups. The activity of the enzyme nitrate reductase in the blood serum on the 30th day of the introduction of exogenous cholesterol increases only 1.15 times, then on the 60th and 90th days of the introduction -1.3 and 1.76 times. In the dynamics of hypercholesterolemia and atherosclerosis in the blood serum, there are noticeable disturbances in the NO-ergic system.

Keywords: Hypercholesterolemia, atherosclerosis, nitrate reductase, endothelin, endothelial dysfunction, NO-ergic system.

E-mail: azimbaykulov81@mail.ru.

INTRODUCTION

Endothelial dysfunction is an early stage in the development of atherosclerosis and is marked by impaired endothelium-dependent vascular relaxation. It is known that the cause of endothelial dysfunction is a decrease in the biological activity of NO, the main mediator secreted by endothelial cells (Chusova, 2019; Suchkova, 2019).

It has now been established that the vascular endothelium plays an extremely important role in the activity of the cardiovascular system. Classical ideas about it as an anatomical barrier that prevents the penetration of blood into the walls of blood vessels have expanded significantly (Fedin et al., 2021). It turned out that the vascular endothelium is a powerful metabolic system that supports vascular homeostasis by performing several important functions: modulating vascular tone, regulating the transport of dissolved substances into the cells of the vascular wall, the growth of these cells, the formation of an extracellular matrix, protecting vessels from the possible adverse effects of circulating blood cells and substances, regulation of chemotactic, proliferative, inflammatory and reparative processes in

response to local damage (Azim, 2021; Kenjayeich et al., 2022; Serebrennikova et al., 2019). These functions of the vascular endothelium are carried out by the synthesis and release of several biologically active compounds in response to mechanical and humoral stimuli. Vasodilator substances produced by the vascular endothelium include NO, prostacyclin (PGI₂), various hyperpolarizing factors and C-natriuretic peptide, vasoconstrictor substances include endothelin-1 (ET-1), angiotensin II, thromboxane A₂ and reactive oxygen species. Endothelial modulators of inflammation are NO, intercellular adhesion molecule-1 (ICAM-1), vascular adhesion molecule-1 (VAFM-1), E-selectin, and nuclear factor kappa B (NF- κ B). Modulation of endothelial hemostasis is carried out by isolating such compounds as plasminogen activator, tissue factor inhibitor, von Willebrand factor, NO, PGI₂, TxA₂, plasminogen activator inhibitor-1 and fibrinogen. The endothelium also takes an active part in the regulation of mitogenesis, angiogenesis, vascular wall permeability, and fluid balance (Ivanov et al., 2020).

It is known that the cause of endothelial dysfunction is

a decrease in the biological activity of NO, the primary mediator secreted by endothelial cells. NO modulates several physiological processes in the body: it inhibits platelet adhesion and aggregation, the proliferation and migration of vascular smooth muscle cells, plays a key role in the interaction of endothelial cells and circulating leukocytes, and also affects the permeability of endothelial cells to lipoproteins and other atherogenic macromolecules. NO is synthesized from L-arginine under the influence of three isoforms of NO synthase: 2 constitutive - endothelial (eNOS) and neuronal (nNOS), one inducible (macrophage, iNOS). They incorporate molecular oxygen into the nitrogen atom in the terminal guanidine group of L-arginine (Kuznetsova, 2021).

eNOS is localized in the caveolae (lacuna-like microsites 50–1000 nm in size) of plasma membrane endothelial cells, where it is associated with caveolin. In this state, eNOS activity is significantly reduced. Under the influence of several receptor-dependent stimuli (acetylcholine, bradykinin, thrombin, ADP, glutamate, substance P, etc.), which increase the calcium concentration in endothelial cells, eNOS is released, it gets activated by calcium-calmodulin, L-arginine leading to the oxidation of L-arginine and subsequent synthesis of a small amount of NO. The formation of NO is also increased by receptor-independent agonists (Ca^{2+} - ionophores, Ca^{2+} -ATP), stretching of the vessel wall, and displacement of blood relative to endothelial cells (known as shear stress), among other factors (Chertok et al., 2020).

NO is a regulatory molecule involved in the regulation of tissue metabolism in normal and various pathological conditions. Today it has been proven that it participates in the regulation of vascular tone, and inhibits platelet aggregation and their adhesion to the walls of blood vessels. Nitric oxide serves as a mediator in the development of physiological and pathological processes in the body. Relaxation of vascular smooth muscle elements under the action of nitroglycerin is explained by the release of NO during the metabolism of this drug. Among patients with myocardial infarction, a reverse correlation has been observed between the level of nitrites/nitrates and risk factors for the development of left ventricular failure and the severe clinical course of myocardial infarction (Vnukov et al., 2019). The study aimed to investigate the molecular mechanisms underlying endothelial dysfunction due to alterations in the nitroergic system in an experimental model of hypercholesterolemia.

MATERIALS AND METHODS

The experiments were carried out on 28 Chinchilla rabbits with an average weight of 2.5-3.0 kg, kept on a standard diet. The model of experimental hypercholesterolemia in experimental animals was reproduced using the Anichkov method. Experimental hypercholesterolemia was caused by oral administration

of dissolved cholesterol in sunflower oil in the ratio of 0.2 g per 1 kg of body weight daily for 3 months.

After 2 months from the start of the experiment, the rabbits were divided into the following groups:

Group 1 - intact (3 rabbits), which were injected with vegetable oil daily at a rate of 1.0 ml/kg through the oral cavity;

Group 2 - model of experimental hypercholesterolemia with water intake - control (5 rabbits);

Group 3 - model of experimental hypercholesterolemia with gemfibrozil 100 mg/kg (5 rabbits);

Group 4 - model of experimental hypercholesterolemia with the intake of chitosan derivative No. 1 at 25 $\mu\text{g}/\text{kg}$ (5 rabbits);

Group 5 - model of experimental hypercholesterolemia with the intake of chitosan derivative No. 2 at 50 $\mu\text{g}/\text{kg}$ (5 rabbits);

Group 6 - model of experimental hypercholesterolemia with heparin at 15 units/kg (5 rabbits).

The action of drugs was studied in dynamics: the initial 3-month condition and after one month of drug administration. The results obtained were compared with those of the control and intact groups. Study of endothelial dysfunction (level of endothelin) by enzyme immunoassay was done using ELIZA reagent (Burova et al., 2019).

The method for determining the level of NO by the sum of metabolites of nitrites and nitrates (NO_2 and NO_3) was carried out according to the method described by Golikov et al. (2006), modified by Metel'skaia and Gumanova (2005). 2.5% phosphoric acid (Sigma, USA) and incubated for 10 min at room temperature. The absorption value was measured at a wavelength of 546 nm on an SF-46 spectrophotometer (Russia). Sodium nitrite (NaNO_2) was used as a standard (Stepanova et al., 2019). Where the calculated coefficient E is the extinction index of the sample.

Determining the activity of nitric oxide synthase (eNOS), to 0.2 ml of the sample was added a reaction system containing 0.1 M Tris- HCl buffer (pH=7.4), which also included CaCl_2 (10 mm), 0.3 ml of an aqueous solution of arginine (substrate eNOS) at a concentration of 80 μM and 0.1 ml of 10 mm aqueous solution of NADPH_2 . Incubation was carried out in a water bath at 37°C for 20 min. The reaction was stopped by introducing 0.02 ml of a 0.02% aqueous solution of sodium azide (NaCN) into the cuvette, and the decrease in extinction at 340 nm was recorded on an SF-46 spectrophotometer (Russia). Control samples were prepared similarly, but instead of NADPH_2 , 0.1 ml of distilled water was added (Burlev and Ilyasova, 2019).

Nitrate reductase activity was determined by the method of Vavilova and Petrovich (1991), NaHCO_3 0.1ml 50m006Dol NADPH, 0.1 ml NaNO_3 ($1 \cdot 10^{-1}\text{M}$). The resulting mixture was incubated at 37°C in a water bath

for 30 minutes. After incubation, the samples were vigorously shaken until complete discoloration and the volume was adjusted to 2.0 ml with distilled water. Then reagents for nitrites were added, including Griess reagent (Eroshenko et al., 2019).

The level of peroxynitrite (ONOO^-) was determined by the oxidation of hydroxylamine (NH_2O^-) formed peroxynitrite. The reaction was started by adding 0.2 ml of a 1.5% aqueous solution of hydroxylamine to 0.2 ml of the sample. 0.1 ml H_2O was added to a blank sample. The reaction was stopped after 10 minutes by adding 1.0 ml of a 4% ammonium molybdate solution. The intensity of the developed colour was measured on an SF-46 at a wavelength of 410 nm against a control sample.

The results obtained were compared with those of the control and intact groups. The digital material was processed by the method of variation statistics.

RESULTS AND DISCUSSION

The NO-ergic system plays the most significant role in

the implementation of its functions by the vascular endothelium and the occurrence of its dysfunction. During the development of the pathology of the vascular system, intracellular signal transmission in the NO_x synthesis system with the participation of eNOS is disrupted. In the dynamics of experimental atherosclerosis, there is a significant decrease in the content of products of nitric oxide, the severity of which corresponds to the progression of hypercholesterolemia. Consequently, the nitric oxide content, assessed based on the quantity of end products, diminishes by 1.29 times on the 30th day of the experiment in comparison to the measurements in intact rabbits. By the 60th day of cholesterol administration, nitric oxide production becomes even more inhibited, showing a decrease of 1.19 and 1.53 times relative to the values of the previous period and the values observed in intact rabbits. As the pathological process progresses, the content of nitric oxide decreases by 1.64 and 2.11 times, respectively, to the values of 30th-day hypercholesterolemia and intact rabbits. Therefore, as experimental atherosclerosis progresses, endothelial nitric oxide production decreases (Table 1).

Table 1. Indicators of the nitroergic blood system in the dynamics of experimental atherosclerosis.

Group, terms (month)	Indicators of the nitroergic system			
	NO_x , $\mu\text{mol/l}$	eNOS, $\mu\text{mol/min*mg protein}$	OONO, $\mu\text{mol/l}$	NR, $\mu\text{mol/min*mg protein}$
Intact	16,68±0,28	35,05±0,76	0,15±0,01	2,72±0,19
Experimental hypercholesterolemia				
1	12,94±0,1	28,29±0,49	0,2±0,01a	3,12±0,11
2	10,91±0,15	25,8±0,73	0,29±0,02	3,54±0,1
3	7,89±0,31	18,05±0,7	0,37±0,01	4,78±0,14

These alterations in the level of nitric oxide in the blood serum may be due to inhibition of endothelial nitric oxide synthase. Indeed, the determination of eNOS activity showed its progressive decrease. Thus, if the activity of the enzyme on the 30th day of cholesterol administration decreased only 1.25 times, then on the 60th and 90th days of the experiment this decrease was 1.36 and 1.94 times, respectively, relative to the values of intact animals. In general, the shifts in the activity of the NOS enzyme that we have identified are consistent with shifts in the level of the product of the NO-ergic system, NO_x . At the same time, the lower the activity of the NOS enzyme, the lower the level of NO_x .

In contrast to the content of NO_x , in the blood serum of rabbits with hypercholesterolemia, an increase in the level of the product of the bioconversion of NO_x —OONO⁻. So, if the level of the latter on the 30th day of the introduction of exogenous cholesterol increases by 1.33 times relative to the values of intact rabbits, then on the

60th and 90th days of the experiment - by 1.93 and 2.47 times respectively.

Consequently, the development of hypercholesterolemia and atherosclerosis is accompanied by an increase in the product of NO_x bioconversion - peroxynitrite (ONOO^-), the strongest oxidizing agent that has a negative effect on cellular structures.

Taking into account that under conditions of hypercholesterolemia the serum level of ONOO^- is noticeably higher than in intact rabbits, the activity of another enzyme of the NO-ergic system involved in the bioconversion of nitric oxide - nitrate reductase. As can be seen from the above data, with hypercholesterolemia there are marked changes in activity and enzyme HP. At the same time, if the activity of the enzyme nitrate reductase in the blood serum on the 30th day of the introduction of exogenous cholesterol increases only 1.15 times, then on the 60th and 90th days of the introduction

-1.3 and 1.76 times. Consequently, hypercholesterolemia and atherosclerosis are accompanied by activation of enzymes involved in the biotransformation of nitric oxide. The obtained data on the activity of the enzyme nitrate reductase are consistent with the data obtained in relation to the level of ONOO^- in blood serum. At the same time, the higher the activity of nitrate reductase, the higher the level of peroxynitrite.

From the data obtained, it becomes obvious that with hypercholesterolemia and atherosclerosis, noticeable disturbances occur in the NO-ergic blood system. Considering that NO in the blood serum is primarily involved in the implementation of the mechanisms for maintaining the functional activity of the vascular endothelium, the genesis of the development of hypertension in the studied pathologies becomes clear. This is confirmed by a decrease in the blood serum level of NO_x in experimental animals, due to the inhibition of the enzyme eNOS in them. Moreover, an increase in the level of peroxynitrite indicates the implementation of the

negative role of the NO-ergic system and indicates the pathological role of these disorders in the genesis of the onset and progression of atherosclerosis.

Our analysis of the ratio of components of the NO-ergic system of blood serum in experimental animals confirms this assumption. The ratio of products of the NO-ergic system of blood serum NO_x and ONOO^- is approximately 111.2: 1, that is, the normal level of NO_x is 111 times higher than the level of peroxynitrite. This ratio is disturbed in animals with hypercholesterolemia due to a noticeable increase in the specific gravity of peroxynitrite, a product of the bioconversion of nitric oxide. At the same time, the ratio of NO_x : ONOO^- becomes lower compared to intact rabbits: 1.72; 2.96 and 5.22 times. An almost similar dynamic is observed in the ratio of the ratio of NOS: nitrate reductase enzymes. Here, the violation of the ratio NOS: nitrate reductase occurs due to the predominant increase in the activity of the enzyme nitrate reductase, which is involved in the transformations of nitric oxide (Table 2).

Table 2. The ratio of individual components of the blood serum system in the dynamics of experimental hypercholesterolemia.

Parameter	Intact group	Experimental hypercholesterolemia, terms (month)		
		1	2	3
NO_x : ONOO^-	111,2 : 1,0	64,7 : 1,0	37,6 : 1,0	21,3 : 1,0
NOS : HP	12,9 : 1,0	9,1 : 1,0	7,3 : 1,0	3,8 : 1,0
NOS : NO_x	2,1 : 1,0	2,2 : 1,0	2,4 : 1,0	2,3 : 1,0
HP : ONOO^-	18,1 : 1,0	15,6 : 1,0	12,2 : 1,0	12,9 : 1,0
NO_x : NOS	0,48 : 1,0	0,46 : 1,0	0,42 : 1,0	0,44 : 1,0
ONOO^- : HP	0,055 : 1,0	0,064 : 1,0	0,082 : 1,0	0,077 : 1,0

To confirm the assumption that, in experimental hypercholesterolemia, disturbances in the NO-ergic system of blood serum are predominantly pathological, and are not a compensatory process, we also analyzed the ratio NOS: NO_x and nitrate reductase: ONOO^- according to the "substrate ratio enzyme" principle. NOS: NO_x ratio in the dynamics of hypercholesterolemia compared with the intact group does not differ significantly, but the ratio of nitrate reductase: ONOO^- markedly impaired.

Consequently, in the dynamics of experimental hypercholesterolemia and atherosclerosis, the violation of the ratio of NO_x : ONOO^- and NOS: nitrate reductase is based primarily on shifts in the ratio of nitrate reductase: ONOO^- , and not in the ratio NOS: NO_x , and ONOO^- is a signal molecule that carries out cell-destructive processes.

With the progression of hypercholesterolemia and hyperbetalipoproteinemia, the production of nitric oxide and the activity of its synthase in endotheliocytes are suppressed, and the content of its active radicals

progressively increases. This is also facilitated by an increase in the activity of nitrate reductase.

CONCLUSION

Experimental hypercholesterolemia is manifested by endothelial dysfunction. This is due to interrelated changes in the level of CRP, endothelin-1 and homocysteine, the severity of which depended on the duration of the experiment and the concentration of cholesterol in low-density lipoprotein, which leads to atherogenesis, disruption of the integrity of the vascular endothelium and its dysfunction. In the dynamics of hypercholesterolemia and atherosclerosis in the blood serum, there are noticeable disturbances in the NO-ergic system. These disorders are characterized by NO_x deficiency due to low NOS activity, as well as the accumulation of peroxynitrite, a nitric oxide bioconversion product, due to an increase in nitrate reductase activity and, apparently, the failure of the antioxidant defence

system. Undoubtedly, the definitions of nitric oxide in the blood serum are accompanied by defective functioning of mechanisms aimed at regulating the functional activity of not only the vascular endothelium but also blood cells, contributing to the launch of the corresponding endothelial mechanisms on the feedback principle, which negatively affects the course and outcome of the studied pathology. This circumstance requires taking into account the violations we have identified in the choice of strategy and tactics for the treatment of hypercholesterolemia and atherosclerosis.

REFERENCES

- Azim B, 2021.** The state of free-radical oxidation of lipids in experimental myocardial infarction in rats. *Eur J Mol Clin Med*, 8(3): 816-820.
- Burlev VA, Ilyasova NA, 2019.** Neurogenic inflammation: neuropeptides and nitric oxide synthases in patients with endometriosis and pelvic pain. *Problemy Reproduktsii*, 25(6).
- Burova NA, Serdyukov SV, Sadovskaya KA, Zharkin NA, 2019.** Biochemical markers of endothelial dysfunction in patients with acute inflammatory diseases of the pelvic organs against the background of various treatment options. *F Snegirev Arch Obstet Gynecol*, 6(1): 27-31. doi: 10.18821/2313-8726-2019-6-1-27-31.
- Chertok VM, Khramova IA, Kotsyuba AY, 2020.** Gasotransmitters in the regulation of the functions of the intraorganic blood vessels of the uterus. *Morphology*, 157(1): 98-111.
- Chusova NA, 2019.** The role of endothelial dysfunction in obesity. *Int Student Sci Bull*, 5-2: 67-67.
- Eroshenko FV, Storchak IG, Chernova IV, 2019.** Evaluation of the state of plants by express diagnostics. *Agrarian Bull Urals*, 7(186): 19-25.
- Fedin AI, Saverskaya EN, Badalyan KR, 2021.** Multimodal therapeutic strategies in the treatment of cerebrovascular disease. *J Neurol Psychiatry*, 121(12): 112-118.
- Golikov PP, Kartavenko VI, Klychnikova EV, Shabanov AK, 2006.** Disturbances of endogenous factors of vascular regulation and oxidative stress depending on the severity of combined injury. *Vestn Ross Akad Med*, 7: 11-15.
- Ivanov AN, Popykhova EB, Tereshkina NE, Stepanova TV, Zlobina OV, Norkin IA, 2020.** Vasomotor function of the endothelium. *Successes Physiol Sci*, 51(4): 82-104.
- Kenjayevich BA, Tashanovich SK, Uzokovich DM, Sayfiyevna YS, Xusniddin qizi KS, 2022.** Changes of basic intermediates in blood in myocardial infarction. *J Posit Sch Psychol*, 6(5): 1775-1781.
- Kuznetsova LA, 2021.** Metabolic syndrome: the effect of adipokines on the L-arginine-NO-synthase-NO signaling pathway. *Acta Biomed Sci*, 6(2): 22-40.
- Metel'skaia VA, Gumanova NG, 2005.** Screening as a method for determining the serum level of nitric oxide metabolites. *Klin Lab Diagn*, 6: 15-8.
- Serebrennikova SN, Guzovskaya EV, Seminsky IZ, 2019.** Nanomolecular mechanisms of metabolic syndrome formation. *Transbaikal Med Bull*, 2: 169-187.
- Stepanova TV, Ivanov AN, Tereshkina NE, Popykhova EB, Lagutina DD, 2019.** Markers of endothelial dysfunction: pathogenetic role and diagnostic significance. *Klin Lab Diagn*, 64(1): 34-41. Russian. doi: 10.18821/0869-2084-2018-63-34-41.
- Suchkova EI, 2019.** Comorbidity in hypertension in outpatient practice: analysis, remote monitoring of blood pressure, correction of metabolic disorders and endothelial dysfunction. Ryazan State Medical University.
- Vavilova TP, Petrovich IA, 1991.** Determination of nitrate reductase activity in mixed saliva. *Vopr Med Khim*, 37(2): 69-72.
- Vnukov VV, Sidorov RV, Gvaldin DY, Milyutina NP, Ananyan AA, Pospelov DY, Plotnikov AA, Shlyk IF, Dolmurzieva NS, 2019.** The role of myeloperoxidase, paraoxonase and nitric oxide system in blood and pericardial fluid in patients with IHD who underwent direct myocardial revascularization. *Adv Gerontol*, 32(1-2): 93-101.

Citation: Kenjayevich BA, 2023. Dynamics of the nitroergic system in experimental hypercholesterolemia. *Int Res J Med Med Sci*, 11(3): 30-34.
